Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib. Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relapses were seen in initial reports. We reviewed the original 300 patient phase 2 FCR study to identify long-Term disease-free survivors. Minimal residual disease (MRD) was assessed posttreatment by a polymerase chain reaction-based ligase chain reaction assay (sensitivity 0.01%). At the median follow-up of 12.8 years, PFS was 30.9% (median PFS, 6.4 years). The 12.8-year PFS was 53.9% for patients with mutated immunoglobulin heavy chain variable (IGHV) gene (IGHV-M) and 8.7%for patientswith unmutated IGHV (IGHV-UM). 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. A plateau was seen on the PFS curve in patientswith IGHV-M, with no relapses beyond 10.4 years in 42 patients (total follow-up 105.4 patient-years). Onmultivariable analysis, IGHV-UM(hazard ratio, 3.37 [2.18-5.21]; P < .001) and del(17p) by conventional karyotyping (hazard ratio, 7.96 [1.02-61.92];P5.048)were significantly associated with inferiorPFS. Fifteen patients with IGHV-Mhad 4-colorMRDflowcytometry (sensitivity 0.01%) performed in peripheral blood, at amedian of 12.8 years posttreatment (range, 9.5-14.7). All were MRD-negative. The high rate of very long-Term PFS in patients with IGHV-M after FCR argues for the continued use of chemoimmunotherapy in this patient subgroup outside clinical trials; alternative strategiesmaybepreferred inpatientswithIGHV-UM, tolimit long-Term toxicity.